ApopLogic Pharmaceuticals, Inc. is a biopharmaceutical company based in Aurora, CO, specializing in the development and commercialization of innovative treatments for a wide range of solid tumors. Their product portfolio includes B201-acetate Breceptin, a synthetic peptide, and AP-300 Fasaret, a biologic, both of which have shown promising results in clinical studies for various cancer types.
The company is actively seeking partnerships and funding to support the clinical development of their products in humans, as well as exploring opportunities in the animal health care space for AP-300. With a focus on targeted therapies and biomarker identification, ApopLogic aims to provide effective treatment options for patients with unmet medical needs in the field of oncology.
Generated from the website